These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27917710)

  • 21. Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy.
    Loughlin G; Romaniega TD; Garcia-Fernandez J; Calvo D; Salgado R; Alonso A; Li X; Arenal A; González-Torrecilla E; Atienza F; Fernández-Avilés F
    J Interv Card Electrophysiol; 2016 Mar; 45(2):149-58. PubMed ID: 26739484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.
    Lu D; Zhang Q; Liu Q; Wang K; Wang S; Shan Q
    J Interv Card Electrophysiol; 2015 Nov; 44(2):105-11. PubMed ID: 26342485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of different anticoagulation therapies on heparin dosage applied to atrial fibrillation patients undergoing atrial fibrillation catheter ablation].
    Yang L; Gao LJ; Yin XM; Guo BL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Aug; 47(8):602-607. PubMed ID: 31434430
    [No Abstract]   [Full Text] [Related]  

  • 24. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'The role of novel oral anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation'.
    Baltogiannis G; Chierchia GB; Conte G; Sieira J; Di Giovanni G; Ciconte G; de Asmundis C; Saitoh Y; Wauters K; Irfan G; Brugada P
    Hellenic J Cardiol; 2016; 57(5):331-337. PubMed ID: 28087311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
    Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
    Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin.
    Zhao Y; Yang Y; Tang X; Yu X; Zhang L; Xiao H
    J Interv Card Electrophysiol; 2017 Apr; 48(3):267-282. PubMed ID: 28078536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
    Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
    J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.
    Kalabalik J; Rattinger GB; Sullivan J; Slugocki M; Carbone A; Rivkin A
    Drugs; 2015 Jun; 75(9):979-98. PubMed ID: 25998374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 36. Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?
    Romero J; Avendano R; Diaz JC; Taveras J; Lupercio F; Di Biase L
    Expert Rev Cardiovasc Ther; 2019 Jan; 17(1):31-41. PubMed ID: 30460874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
    Garton AB; Dudzinski J; Kowey PR
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1411-8. PubMed ID: 25216104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Snipelisky D; Ray JC; Ung R; Duart M; Kauffman C; Kusumoto F
    J Interv Card Electrophysiol; 2014 Dec; 41(3):231-6. PubMed ID: 25380703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.
    Larsen TB; Potpara T; Dagres N; Proclemer A; Sciarrafia E; Blomström-Lundqvist C;
    Europace; 2015 May; 17(5):819-24. PubMed ID: 25926476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.